Novo Nordisk reports adjusted operating profi...

Novo Nordisk's Q2 2026 profits rise on an adjusted basis, but headline profit falls sharply.

Risk flags

• ●Reported operating profit fell 16% at CER in Q2 2026, driven by a DKK 2.6 billion rebate provision reversal and DKK 6.3 billion in impairment charges, highlighting the company’s exposure to regulatory and pipeline asset risks. Such large non-cash charges can mask underlying operational trends and may recur if pipeline assets underperform.
• ●Forward guidance for 2026 projects adjusted sales and operating profit growth between 0% and -6% at CER, indicating management expects flat or negative performance despite recent product launches. This suggests limited near-term growth potential and raises questions about the sustainability of recent momentum.
• ●Key claims around GLP-1 volume growth, US rebate adjustments, and market leadership for Wegovy® are not supported by quantitative disclosures, reducing transparency and making it difficult to independently verify the drivers of growth. The lack of cash flow, net income, and segment-level data further limits the ability to assess underlying profitability and risk.

Bottom line

Novo Nordisk’s Q2 2026 results show a mixed picture: adjusted operating profit and sales are up, but reported operating profit is down sharply due to exceptional items. The company’s narrative emphasizes product momentum and regulatory wins, but the numbers point to a deteriorating financial trajectory and management’s own guidance signals flat or negative growth for the rest of 2026. Several key claims, especially around market leadership and new market uptake, lack supporting data. The absence of cash flow and segment disclosures leaves gaps in the investment case. For investors, the most important takeaway is that while core operations remain resilient, headline profit is under pressure and near-term growth prospects appear limited. More detailed disclosure on profitability drivers and cash generation would be needed to strengthen the investment thesis.

Announcement summary

(LSE/AIM:0QIU) Novo Nordisk reported an adjusted operating profit of DKK 33,389 million for Q2 2026 and raised its full-year outlook. Q2 2026 reported sales increased by 3% at CER, while adjusted sales increased by 7% at CER, driven by GLP-1 volume growth and favourable US rebate adjustments. Reported operating profit for Q2 2026 decreased by 16% at CER, impacted by a DKK 2.6 billion rebate provision reversal in Q2 2025 and non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion). Wegovy® pill prescriptions in the US exceeded 265,000 for the week ending 17 July, and more than 5 million prescriptions have been reached since launch. Wegovy® pill was launched in the UAE in June and in the UK in July, with additional launches planned in other select markets. The company projects adjusted sales growth for 2026 to be 0% to -6% at CER and adjusted operating profit growth to be 0% to -6% at CER. The roll-out of Wegovy® 7.2 mg single-dose pen across the EU is planned in the second half of 2026.

Disagree with this article?